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OBJECTIVE: To examine the degree of association between
medical conditions and work-loss and to estimate the costs asso-
ciated with work absenteeism among workers in US during
2001. METHODS: Data were extracted from the 2001 Medical
Expenditure Panel Survey, a nationally representative survey of
medical care use and expenditures conducted by the Agency for
Healthcare Research and Quality. The study sample included
heads of household, 23–65 years old, who were employed for
the entire year (not self employed). Of interest was the incidence
of work loss during 2001. Additional information was collected
on number of work days lost during the year, the associated
medical conditions based on ICD-9-CM codes and other demo-
graphic and employment characteristics. Logistic regression was
used to assess association of medical conditions with work
absenteeism controlling for other characteristics. RESULTS: In
total, 4687 persons were identiﬁed. Mean age was 40.6 years,
54.4% were male, 18.8% were non-white, and 51.2% had at
least high-school education. Workers earned on average $16.8
per-hour, and worked 41.5 hours-per-week. Work loss was
reported by 2614 persons (55.8%), who on the average lost 8.5
work-days per year (median 3.3 days), valued at $1069 based
on reported hourly wages (median $365). After adjusting for
other demographic and employment characteristics, logistic
regression analysis revealed that medical conditions were signif-
icant predictors of absenteeism. Speciﬁcally (odds ratio; 95%
conﬁdence intervals): infectious diseases (5.0; 4.1–6.2), mental
disorders (1.6; 1.3–2.0), respiratory system (3.3; 2.9–3.8), diges-
tive system (2.5; 2.0–3.1), and musculoskeletal system (1.8;
1.6–2.2). Absenteeism was more likely to be reported among
females (1.4; 1.3–1.7) and those with sick beneﬁts (1.3; 1.1–1.5).
CONCLUSION: Medical conditions are signiﬁcant predictors of
work loss and associated costs. To reduce incidence and costs
associated with work loss, effective policies would need to
address the use of effective disease prevention measures and
chronic disease treatments.
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OUTCOMES OF TECHNOLOGY APPLICATION ON
PHARMACISTS JOB PERFORMANCE: THE ROLE OF
PERSONAL DIGITAL ASSISTANTS
Sikri S, Sansgiry SS
University of Houston, Houston,TX, USA
OBJECTIVE: The objective of this study was to evaluate the out-
comes associated with the use of Personal Digital Assistants
(PDAs) by pharmacists’ working in retail and hospital setting
using Extended Technology Acceptance Model (ETAM).
METHODS: A cross-sectional study was conducted by admin-
istering a survey to pharmacists (N = 285, Retail = 138, Hospi-
tal = 147) in the Houston metropolitan area. A prevalidated
questionnaire using thirty items, ﬁve-point strongly disagree
(1)—strongly agree (5) Likert scale was used to measure phar-
macists’ perceived usefulness and intention to use PDAs. Data
along with demographic information such as age, gender, edu-
cation, income and practice setting were collected, coded, and
analyzed using SAS at a set priori signiﬁcance level of 0.05.
Descriptive, correlation and stepwise regression analyses were
performed to predict pharmacists’ intention to use PDAs.
RESULTS: Among the surveyed population only 35% of retail
pharmacists’ owned a PDA in comparison to 64% of hospital
pharmacists’. Overall, pharmacists’ in both retail and hospital
settings indicated that PDAs’ can improve job efﬁciency (55%)
and be a cost effective tool (63%) in providing patient care.
Further, spearman correlation analysis indicated high correlation
between perceived usefulness and intention to use PDAs in hos-
pital setting (r = 0.78, p < 0.001). However, in retail setting result
demonstrability, tangibility and communicability of the results
associated with the use of PDAs’ was highly correlated with
intention to use (r = 0.62, p < 0.001). ETAM was able to explain
55% and 71% of variance in retail and hospital pharmacists’
intention to use PDAs respectively. CONCLUSIONS: The ETAM
model, speciﬁcally, variables such as perceived usefulness, atti-
tude, and result demonstrability were useful in predicting phar-
macist’s intention to use PDAs in both the settings. As technology
advances, PDAs would provide pharmacists’ an affective tool for
improving efﬁciency in job and subsequently the patient care
related outcomes.
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OBJECTIVES: To assess the quality of the health economic
material submitted to the Swedish Pharmaceutical Beneﬁts Board
(PBB) as part of the application for reimbursement for new phar-
maceuticals. The cost per QALY in the submitted material and
how this has related to the PBB’s decision is also presented.
METHODS: The health economic evaluations were reviewed
independently by two reviewers against two check lists, marking
each question Yes/No/Not Applicable. The checklists used were:
1) The PBB Guidelines transformed into yes or no questions and
2) The QHES check list, which is a validated instrument. The
central estimate, or base case, cost effectiveness was collected
(preferably cost per QALY) as well as whether the application
was accepted or rejected by the PBB. RESULTS: The scores on
the PBB check list range from 0.24 to 0.87 and on the QHES
from 0.09 to 1, with a mean quality of 0.61 and 0.67 respec-
tively. Due to Swedish-speciﬁc criteria in the PBB list, there is
only a modest correlation between the two instruments of 0.7.
The baseline cost per QALY in the applications range from neg-
ative values (i.e. a cost-saving drug) to approximately 65,000
Euros. There was a low observed correlation between quality
score and acceptance by the PBB. Likewise, the correlation
between cost per QALY and decision to accept/reject is low or
non-existent. CONCLUSIONS: 1) Health economic material as
part of applications to PBB varies heavily in quality. 2) Due to
the relatively small number of applications supported by sub-
stantial health economic evidence and the even fewer rejections,
it is difﬁcult to draw ﬁrm conclusions regarding the value the
PBB places on a QALY.
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OBJECTIVES: Introduction of a compulsory economic evalua-
tion policy for pharmaceutical reimbursement was enacted in
Korea in 2000, but has yet to be fully implemented. Concerns
about the quality and availability of population speciﬁc clinical
data, treatment patterns, health care prices and subsequent 
cost-effectiveness data have been raised. We evaluated the quality
of Korean economic evaluation studies of pharmaceuticals to
understand gaps. From this, we propose policy options that
might strengthen the research infrastructure in order to support
such studies. METHODS: We reviewed 21 published studies of
drugs conducted between 1996 and 2004. We utilized a pub-
